Catenacci, D. V. T., Park, H., Lockhart, A. C., Gold, P. J., Enzinger, P. C., Nordstrom, J. L., … Bang, Y.-J. (2018). Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 36). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.

Catenacci, Daniel V. T., Haeseong Park, A Craig Lockhart, Philip Jordan Gold, Peter C. Enzinger, Jeffrey L. Nordstrom, Sam Hong, et al. “Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.

Catenacci DVT, Park H, Lockhart AC, Gold PJ, Enzinger PC, Nordstrom JL, et al. Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2018.

Catenacci, Daniel V. T., et al. “Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).” JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 4, AMER SOC CLINICAL ONCOLOGY, 2018.

Catenacci DVT, Park H, Lockhart AC, Gold PJ, Enzinger PC, Nordstrom JL, Hong S, Hochster HS, Kelly RJ, Uronis HE, Bendell JC, Oh SC, Park SH, Kim YH, Kang Y-K, Lee K-W, Ng MCH, Wigginton JM, Davidson-Moncada JK, Bang Y-J. Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2018.